From Academic Discovery to Clinical Trials: Transitional Priorities
Moving a drug from academic discovery to clinical trials is one of the most critical phases in pharmaceutical development. Academic research often focuses on understanding disease mechanisms and identifying potential targets
Regulatory Pathways FDA and EMA – Are You Prepared for Ongoing AI Supervision?
Regulatory pathways in the United States and Europe are becoming more complex. The FDA and the EMA continue to raise expectations for data quality, transparency, and oversight. At the same time, regulators are expanding their use of advanced digital tools, including artificial intelligence, to review submissions, monitor compliance, and identify risk.
Navigating Intense Drug Market Pressures
Today’s global drug market faces more pressure than ever before. Pharmaceutical companies deal with higher development costs, tougher regulations, stricter pricing, and more competition from generics and biosimilars. Meanwhile, patients, payers, and governments want quicker access to safe and effective treatments. These factors are changing how companies plan, develop, launch, and manage products over time.
To succeed, companies need to know what causes market pressure and how it shapes their decisions. They also have to adjust their strategies while keeping quality, safety, and compliance intact.